These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22926613)

  • 21. Possible neuroleptic malignant syndrome associated with paliperidone.
    Duggal HS
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):477-8. PubMed ID: 18070861
    [No Abstract]   [Full Text] [Related]  

  • 22. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
    Jones A
    J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
    Harrington CA; English C
    Int Clin Psychopharmacol; 2010 Nov; 25(6):334-41. PubMed ID: 20706126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Paliperidone].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Aug; 29(8):280-2. PubMed ID: 16927595
    [No Abstract]   [Full Text] [Related]  

  • 25. Hyperprolactinaemia during treatment with paliperidone.
    Skopek M; Manoj P
    Australas Psychiatry; 2010 Jun; 18(3):261-3. PubMed ID: 20429680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation of antipsychotic drug therapy.
    Mitchell JE
    Psychosomatics; 1981 Mar; 22(3):241-7. PubMed ID: 6111827
    [No Abstract]   [Full Text] [Related]  

  • 27. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 28. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 29. Reversible withdrawal dyskinesia associated with quetiapine.
    Michaelides C; Thakore-James M; Durso R
    Mov Disord; 2005 Jun; 20(6):769-70. PubMed ID: 15747370
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute renal failure after paliperidone overdose: a case report.
    Liang CS; Bai YM; Liou YJ; Chou YH
    J Clin Psychopharmacol; 2012 Feb; 32(1):128. PubMed ID: 22217944
    [No Abstract]   [Full Text] [Related]  

  • 32. Parkinsonism and rabbit syndrome after discontinuation of low-dose ziprasidone and concomitant initiation of sertraline.
    Gray JA
    J Clin Psychopharmacol; 2012 Feb; 32(1):142-3. PubMed ID: 22217953
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of paliperidone-palmitate-induced tardive dyskinesia.
    Lally J; Byrne F; Walsh E
    Gen Hosp Psychiatry; 2013; 35(2):213.e5-7. PubMed ID: 22703608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone (Invega) for schizophrenia.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):21-3. PubMed ID: 17351558
    [No Abstract]   [Full Text] [Related]  

  • 36. New drug for schizophrenia.
    FDA Consum; 2007; 41(2):6. PubMed ID: 17590895
    [No Abstract]   [Full Text] [Related]  

  • 37. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
    Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
    Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.
    Berwaerts J; Lane R; Nuamah IF; Lim P; Remmerie B; Hough DW
    J Affect Disord; 2011 Mar; 129(1-3):252-60. PubMed ID: 20947174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence of tardive dyskinesia.
    Kane JM; Woerner M; Lieberman JA; Weinhold P; Florio W; Rubinstein M; Rotrosen J; Kurucz J; Mukherjee S; Bergmann K
    Psychopharmacol Bull; 1985; 21(1):136-9. PubMed ID: 2858906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.